From @WSJopinion: If Marty Makary and Vinay Prasad really want to prove they’re not impeding life-saving treatments, they’ll approve Replimune’s RP1 immunotherapy for metastatic melanoma, which the agency rejected this summer https://t.co/cDT7st0w6w ...